The Credibility Tax in Functional Beverage
The functional beverage category has won the mainstream. The cost of winning has been a definition so loose that the word itself is starting to lose its meaning, and that has consequences operators are only beginning to feel.
A lot of brands in the category right now are marketing a feeling rather than delivering one. The label says the drink will help you focus, calm down, recover, or sleep. Some do. Most do not, or they do it so faintly that you could not reliably tell the difference between the drink and a glass of water with a label on it. That gap between what's promised and what's delivered is wellness theater, and it is currently the biggest threat to the category's credibility.
What Wellness Theater Looks Like
The pattern is familiar. A trending ingredient gets a sprinkle of inclusion in a beverage formulation, well below any dose that would produce a perceptible effect. The label features the ingredient prominently. The marketing leans into outcomes the formulation cannot actually deliver. The brand collects revenue on the consumer's belief that something is happening, knowing nothing is.
This is not about brands operating in bad faith. Most of the time it's operators who saw the category growing and wanted a piece of it, without taking on the harder problem of building a real formulation. Formulation is expensive. Clinical backing is expensive. Dosing at efficacious levels eats into margin. The shortcut is to take the marketing claim and skip the chemistry that supports it.
The Cost Gets Paid Down the Aisle
When a consumer pays a premium for a functional beverage and feels nothing, they do not conclude that the category is broken. They conclude the promise was empty, and they carry that skepticism into every functional beverage they encounter next.
That skepticism is a tax. It gets paid by the operators who are doing the work properly. The brands formulating at real dose levels, sourcing ingredients with clinical backing, charging what those inputs actually cost: they have to spend marketing dollars not just on acquisition but on re-convincing a consumer base that has learned to distrust the category. The brands cutting corners get to free-ride on the credibility built by the operators who don't.
That is a structural problem, not a marketing problem, and as the category continues to fragment the tax is going up.
Operator Discipline Is the Only Real Defense
I am not arguing for regulatory intervention. I am arguing for operator discipline. The brands that treat formulation as the hardest problem in the business, rather than the easiest one to outsource, are the ones that will still be here in ten years.
That means investing in clinical work that does not make the label louder. It means dosing at levels the marketing team would prefer to round down for margin reasons. It means turning down the trending ingredient when the available science does not support the claim you would want to make about it. It is slower, more expensive, and harder to defend in a quarterly review.
The brands that will survive contact with a discerning consumer are the ones treating those costs as the price of building something worth owning.
~
This argument is part of an ongoing series, The Future is Fluid, at The Proof is in the Pour.
